FdaApplication
BLA 125527
Identifiers
- fda_app_no: BLA125527
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB |
| application_type | BLA |
Revenue by product
OPDIVO
| Period | Revenue |
|---|---|
| Q2 2026 | $2.7B |
| Q1 2026 | $2.3B |
| Q4 2025 | $2.8B |
| Q3 2025 | $2.6B |
| Q2 2025 | $2.6B |
| Q1 2025 | $2.3B |
| Q4 2024 | $2.5B |
| Q3 2024 | $2.4B |
| Q2 2024 | $2.4B |
| Q1 2024 | $2.1B |
| Q4 2023 | $2.4B |
| Q3 2023 | $2.3B |
| Q2 2023 | $2.1B |
| Q1 2023 | $2.2B |
| Q4 2022 | $2.2B |
| Q3 2022 | $2.0B |
| Q2 2022 | $2.1B |
| Q1 2022 | $1.9B |
| Q4 2021 | $2.0B |
| Q3 2021 | $1.9B |
| Q2 2021 | $1.9B |
| Q1 2021 | $1.7B |
| Q4 2020 | $1.8B |
| Q3 2020 | $1.8B |
| Q2 2020 | $1.7B |
| Q1 2020 | $1.8B |
| Q4 2019 | $1.8B |
| Q3 2019 | $1.8B |
| Q2 2019 | $1.8B |
| Q1 2019 | $1.8B |
| Q4 2018 | $1.8B |
| Q3 2018 | $1.8B |
| Q2 2018 | $1.6B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OPDIVO | NIVOLUMAB | 100MG/10ML | INJECTABLE;INJECTION |
| OPDIVO | NIVOLUMAB | 40MG/4ML | INJECTABLE;INJECTION |
2 products